PureIR
中文
Menu
About PureIR Yonghe MedicalBeauty FarmAngelalignChaoju Eye CareYidu Tech Editorial method

HKEX 02158 · Unpaid pilot profile

Yidu Tech

Yidu Tech Inc.

Yidu Tech uses YiduCore as medical-intelligence infrastructure across AI for Medical, AI for Life Sciences and AI for Care. In FY2026 it reported revenue of RMB819.298 million, profit for the year of RMB78.766 million and a gross margin of 36.4%; at 31 March 2026 it served 133 top hospitals in China and 54 regulators and policymakers, covering more than 12,000 hospitals.

Disclosure through2026-03-31 Page reviewed2026-07-17 Listed onHong Kong Stock Exchange
Official investor-relations website ir@yidutech.com YiduCore · FY2026 annual results · PDF page 3

This is an unpaid PureIR pilot independently prepared from formal disclosure. The company did not commission or pay for the profile and did not participate in any rating or investment judgement.

Turning medical data into a better healthcare future with AI 00

Press and let data pass through YiduCore to illuminate three healthcare pathways

  1. 01Trusted data governance
  2. 02AI for Medical
  3. 03AI for Life Sciences
  4. 04AI for Care

An editorial metaphor for the disclosed medical-intelligence infrastructure and three businesses; it does not depict real personal-data flows or individual clinical outcomes.

RMB78.8m Profit for the year Year ended 31 March 2026 133 hospitals Top-hospital clients in China As at 31 March 2026 HK$0.04/share Proposed final dividend Year ended 31 March 2026 Continue through the disclosure

Disclosure highlights

Latest disclosed facts

Cover of Yidu Tech FY2025 annual report
Yidu Tech FY2025 annual report · HKEX; latest FY2026 data come from the annual results announcement
01

Profit for the year

RMB78.8m

FY2025 recorded a loss of RMB135.223 million; the company achieved its first full-year profit in FY2026.

Year ended 31 March 2026 · RMB million HKEX · PDF page 1
02

Top-hospital clients in China

133 hospitals

AI for Medical also served 54 regulators and policymakers, with solutions covering more than 12,000 hospitals.

As at 31 March 2026 · top hospitals HKEX · PDF page 3
03

Proposed final dividend

HK$0.04/share

A Board recommendation subject to shareholder approval at the annual general meeting scheduled for 28 August 2026.

Year ended 31 March 2026 · HKD per share HKEX · PDF page 22

Disclosure reading

How to read the disclosure

PureIR disclosure synthesis

From narrowing losses to a full-year profit

FY2026 revenue increased by 14.6%, gross profit by 24.8% and gross margin rose from 33.5% to 36.4%; profit for the year turned positive at RMB78.766 million. Full-year net operating cash outflow narrowed to RMB21.998 million, while second-half net operating cash flow was positive at RMB29.3 million.

HKEX · PDF page 2

PureIR disclosure synthesis

Three businesses connect care, life sciences and health management

AI for Medical, AI for Life Sciences and AI for Care generated FY2026 revenue of RMB381.034 million, RMB270.416 million and RMB167.848 million, increasing by 10.2%, 9.4% and 37.6%, respectively.

HKEX · PDF page 1

PureIR disclosure synthesis

YiduCore as medical-intelligence infrastructure

At 31 March 2026, YiduCore had cumulatively processed and analysed approximately 9 billion authorised real-world medical records covering more than 1.32 billion patient visits; its specialised disease repository covered more than 100 disease categories.

HKEX · PDF page 3

Business model

Business revenue

AI for Medical revenue

RMB 381.034 million FY2026 PDF page 30

AI for Life Sciences revenue

RMB 270.416 million FY2026 PDF page 30

AI for Care revenue

RMB 167.848 million FY2026 PDF page 30

Annual series

Revenue mix by business (RMB)

Revenue mix by business (RMB), unit: RMB million 885 664 442 221 0 FY2025FY2026 AI for Medical revenue FY2025: 345.9 RMB million AI for Life Sciences revenue FY2025: 247.1 RMB million AI for Care revenue FY2025: 122.0 RMB million AI for Medical revenue FY2026: 381.0 RMB million AI for Life Sciences revenue FY2026: 270.4 RMB million AI for Care revenue FY2026: 167.8 RMB million
Period: complete fiscal years; business revenue follows company definitions; unit：RMB million；type: company disclosure. FY2026 formal disclosure, PDF page 30
View exact values and source pages
MetricPeriodValueSource
AI for Medical revenueFY2025RMB 345.888 millionPDF page 30
AI for Life Sciences revenueFY2025RMB 247.112 millionPDF page 30
AI for Care revenueFY2025RMB 121.979 millionPDF page 30
AI for Medical revenueFY2026RMB 381.034 millionPDF page 30
AI for Life Sciences revenueFY2026RMB 270.416 millionPDF page 30
AI for Care revenueFY2026RMB 167.848 millionPDF page 30

Structured disclosure

Financial performance

Profitability milestone

FY2026: first full-year profit since listing

FY2026 · 1 April 2025 to 31 March 2026
RMB 78.766 million

Previous fiscal year: RMB -135.223 million

HKEX filing · PDF page 24

Revenue

RMB 819.298 million FY2026 · 1 April 2025 to 31 March 2026 PDF page 24

Gross profit

RMB 298.496 million FY2026 · 1 April 2025 to 31 March 2026 PDF page 24

Profit/(loss) for the year

RMB 78.766 million FY2026 · 1 April 2025 to 31 March 2026 PDF page 24

Annual series

Revenue and gross profit (RMB)

Revenue and gross profit (RMB), unit: RMB million 1,336 1,002 668 334 0 FY2022FY2023FY2024FY2025FY2026 Revenue FY2022: 1,237.2 RMB million Revenue FY2023: 804.7 RMB million Revenue FY2024: 807.1 RMB million Revenue FY2025: 715.0 RMB million Revenue FY2026: 819.3 RMB million Gross profit FY2022: 399.4 RMB million Gross profit FY2023: 274.5 RMB million Gross profit FY2024: 339.4 RMB million Gross profit FY2025: 239.2 RMB million Gross profit FY2026: 298.5 RMB million
Period: complete fiscal years; Yidu Tech's fiscal year ends on 31 March; FY2026 covers 1 April 2025 through 31 March 2026.; unit：RMB million；type: company disclosure. FY2025 formal disclosure, PDF page 268; FY2026 formal disclosure, PDF page 24

Annual series

Profit/(loss) for the year (RMB)

Profit/(loss) for the year (RMB), unit: RMB million 146 -99 -344 -589 -834 FY2022FY2023FY2024FY2025FY2026 Profit/(loss) for the year FY2022: -766.4 RMB million Profit/(loss) for the year FY2023: -632.4 RMB million Profit/(loss) for the year FY2024: -221.2 RMB million Profit/(loss) for the year FY2025: -135.2 RMB million Profit/(loss) for the year FY2026: 78.8 RMB million
Period: complete fiscal years; Yidu Tech's fiscal year ends on 31 March; FY2026 covers 1 April 2025 through 31 March 2026.; unit：RMB million；type: company disclosure. FY2025 formal disclosure, PDF page 268; FY2026 formal disclosure, PDF page 24
View exact values and source pages
MetricPeriodValueSource
RevenueFY2022 · 1 April 2021 to 31 March 2022RMB 1,237.2 millionPDF page 268
Gross profitFY2022 · 1 April 2021 to 31 March 2022RMB 399.445 millionPDF page 268
Profit/(loss) for the yearFY2022 · 1 April 2021 to 31 March 2022RMB -766.36 millionPDF page 268
RevenueFY2023 · 1 April 2022 to 31 March 2023RMB 804.7 millionPDF page 268
Gross profitFY2023 · 1 April 2022 to 31 March 2023RMB 274.53 millionPDF page 268
Profit/(loss) for the yearFY2023 · 1 April 2022 to 31 March 2023RMB -632.361 millionPDF page 268
RevenueFY2024 · 1 April 2023 to 31 March 2024RMB 807.076 millionPDF page 268
Gross profitFY2024 · 1 April 2023 to 31 March 2024RMB 339.445 millionPDF page 268
Profit/(loss) for the yearFY2024 · 1 April 2023 to 31 March 2024RMB -221.242 millionPDF page 268
RevenueFY2025 · 1 April 2024 to 31 March 2025RMB 714.979 millionPDF page 268
Gross profitFY2025 · 1 April 2024 to 31 March 2025RMB 239.182 millionPDF page 268
Profit/(loss) for the yearFY2025 · 1 April 2024 to 31 March 2025RMB -135.223 millionPDF page 268
RevenueFY2026 · 1 April 2025 to 31 March 2026RMB 819.298 millionPDF page 24
Gross profitFY2026 · 1 April 2025 to 31 March 2026RMB 298.496 millionPDF page 24
Profit/(loss) for the yearFY2026 · 1 April 2025 to 31 March 2026RMB 78.766 millionFY2026 covers 1 April 2025 through 31 March 2026; the company reported its first full-year profit since listing.PDF page 24

Structured disclosure

Operating metrics

Top-hospital clients in China

133 hospitals 2026-03-31 PDF page 3

Regulator and policymaker clients

54 organisations 2026-03-31 PDF page 3

Hospitals covered by solutions

12,000 hospitals 2026-03-31 PDF page 3

Active health-platform users

22 million users 2026-03-31 PDF page 3

Authorised medical records processed and analysed

9 billion records 2026-03-31 PDF page 3

Patient visits covered

1.32 billion visits 2026-03-31 PDF page 3

Life-sciences clients

98 clients FY2026 PDF page 3

Clinical studies completed

516 studies FY2026 PDF page 3
View exact values and source pages
MetricPeriodValueSource
Top-hospital clients in China2026-03-31133 hospitalsPDF page 3
Regulator and policymaker clients2026-03-3154 organisationsPDF page 3
Hospitals covered by solutions2026-03-3112,000 hospitalsMore than 12,000 hospitals were covered.PDF page 3
Life-sciences clientsFY202698 clientsPDF page 3
Clinical studies completedFY2026516 studiesPDF page 3
Active health-platform users2026-03-3122 million usersThe disclosed number surpassed 22 million.PDF page 3
Authorised medical records processed and analysed2026-03-319 billion recordsThe company disclosed approximately 9 billion records.PDF page 3
Patient visits covered2026-03-311.32 billion visitsThe disclosed coverage exceeded 1.32 billion patient visits.PDF page 3

Structured disclosure

Cash flow

Net operating cash flow

RMB -21.998 million FY2026 · 1 April 2025 to 31 March 2026 PDF page 1

Cash and cash equivalents

RMB 664.764 million 2026-03-31 PDF page 26

Term deposits

RMB 1,392.61 million 2026-03-31 PDF page 26

Annual series

Net operating cash flow (RMB)

Net operating cash flow (RMB), unit: RMB million 49 -129 -307 -486 -664 FY2022FY2023FY2024FY2025FY2026 Net operating cash flow FY2022: -614.7 RMB million Net operating cash flow FY2023: -357.0 RMB million Net operating cash flow FY2024: -326.4 RMB million Net operating cash flow FY2025: -248.8 RMB million Net operating cash flow FY2026: -22.0 RMB million
Period: complete fiscal years; Yidu Tech's fiscal year ends on 31 March; FY2026 covers 1 April 2025 through 31 March 2026.; unit：RMB million；type: company disclosure. FY2022 formal disclosure, PDF page 151; FY2023 formal disclosure, PDF page 155; FY2024 formal disclosure, PDF page 166; FY2025 formal disclosure, PDF page 176; FY2026 formal disclosure, PDF page 1
View exact values and source pages
MetricPeriodValueSource
Net operating cash flowFY2022 · 1 April 2021 to 31 March 2022RMB -614.676 millionPDF page 151
Net operating cash flowFY2023 · 1 April 2022 to 31 March 2023RMB -357.013 millionPDF page 155
Net operating cash flowFY2024 · 1 April 2023 to 31 March 2024RMB -326.383 millionPDF page 166
Net operating cash flowFY2025 · 1 April 2024 to 31 March 2025RMB -248.814 millionPDF page 176
Net operating cash flowFY2026 · 1 April 2025 to 31 March 2026RMB -21.998 millionPDF page 1
Net operating cash flowH2 FY2026RMB 29.3 millionPDF page 2
Cash and cash equivalents2026-03-31RMB 664.764 millionPDF page 26
Term deposits2026-03-31RMB 1,392.61 millionPDF page 26

Structured disclosure

Shareholder returns

Proposed final dividend

HKD 0.04/share FY2026 PDF page 22

Shares repurchased during the year

50.015 million shares FY2026 PDF page 21

Aggregate share-repurchase consideration

HKD 283.535 million FY2026 PDF page 21
View exact values and source pages
MetricPeriodValueSource
Proposed final dividendFY2026HKD 0.04/sharePDF page 22
Shares repurchased during the yearFY202650.015 million sharesPDF page 21
Aggregate share-repurchase considerationFY2026HKD 283.535 millionPDF page 21

Leadership profile

Senior management

Roles and biographies follow formal disclosure. Portraits are used only when published on the company’s official website.

1 / 3

Official market reference

Latest quote on HKEX

PureIR does not display or redistribute market-price data.

View 02158 on HKEX ↗

Formal disclosure

Principal risks

Technology iteration and commercial execution

The company identifies keeping pace with rapid changes in AI, big-data analytics and other technologies, together with managing business growth and expansion, as principal risks and uncertainties.

HKEX · PDF page 28

Healthcare data, privacy and licences

Continued access to and accurate, efficient processing of healthcare data, compliance with data-protection and privacy laws, and obtaining and maintaining required licences, permits and approvals are formally disclosed principal risks.

HKEX · PDF page 28

Contractual-arrangement structure

The company discloses that an adverse PRC regulatory finding or change in interpretation could result in severe consequences, including invalidation of contractual arrangements and loss of interests in relevant operations; contractual control may also be less effective than direct ownership.

HKEX · PDF page 31

Receivables and credit risk

The Group's credit risk principally relates to bank deposits, contract assets, trade receivables and other financial assets at amortised cost; trade receivables and contract assets are assessed under an expected-credit-loss model.

HKEX · PDF page 205

Evidence

Formal sources and public data

2025 Annual Report274 PDF pages2024 Annual Report268 PDF pages2023 Annual Report256 PDF pages2022 Annual Report260 PDF pagesAnnual Results Announcement for the Fiscal Year Ended 31 March 202636 PDF pagesDownload structured JSON →